Biologics Contract Development Market by Source (Mammalian, Microbial), Type (Molecular Therapy, Monoclonal Antibodies, Recombinant Proteins), Disease Indication, Phase, Service Type, End-User - Global Forecast 2023-2030

Biologics Contract Development Market by Source (Mammalian, Microbial), Type (Molecular Therapy, Monoclonal Antibodies, Recombinant Proteins), Disease Indication, Phase, Service Type, End-User - Global Forecast 2023-2030


The Biologics Contract Development Market is projected to reach USD 14.28 billion by 2030 from USD 5.87 billion in 2022, at a CAGR of 11.74% during the forecast period.

Market Segmentation & Coverage:

This research report analyzes various sub-markets, forecasts revenues, and examines emerging trends in each category to provide a comprehensive outlook on the Biologics Contract Development Market.
  • Based on Source, market is studied across Mammalian and Microbial. The Microbial is projected to witness significant market share during forecast period.
  • Based on Type, market is studied across Molecular Therapy, Monoclonal Antibodies, Recombinant Proteins, and Vaccines. The Molecular Therapy is projected to witness significant market share during forecast period.
  • Based on Disease Indication, market is studied across Cardiovascular Disorders, Hematological Disorders, Immunological Disorders, and Oncology. The Hematological Disorders is projected to witness significant market share during forecast period.
  • Based on Phase, market is studied across Phase I, Phase II, Phase III, and Preclinical. The Phase II is projected to witness significant market share during forecast period.
  • Based on Service Type, market is studied across Cell Line Development and Process Development. The Cell Line Development is further studied across Mammalian and Microbial. The Process Development is further studied across Downstream and Upstream. The Downstream is further studied across Impurity, Isolation, & Identification, Pharmaceutical Analysis, and Physicochemical Characterization. The Upstream is further studied across Mammalian and Microbial. The Process Development is projected to witness significant market share during forecast period.
  • Based on End-User, market is studied across Biopharmaceutical Companies and Research Laboratories. The Biopharmaceutical Companies is projected to witness significant market share during forecast period.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Asia-Pacific is projected to witness significant market share during forecast period.
Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is an indispensable tool for assessing the Biologics Contract Development Market. It comprehensively evaluates vendors, analyzing key metrics related to Business Strategy and Product Satisfaction. This enables users to make informed decisions tailored to their specific needs. Through advanced analysis, vendors are categorized into four distinct quadrants, each representing a different level of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V). Be assured that this insightful framework empowers decision-makers to navigate the market with confidence.

Market Share Analysis:

The Market Share Analysis offers invaluable insights into the vendor landscape Biologics Contract Development Market. By evaluating their impact on overall revenue, customer base, and other key metrics, we provide companies with a comprehensive understanding of their performance and the competitive environment they confront. This analysis also uncovers the level of competition in terms of market share acquisition, fragmentation, dominance, and industry consolidation during the study period.

Key Company Profiles:

The report delves into recent significant developments in the Biologics Contract Development Market, highlighting leading vendors and their innovative profiles. These include AbbVie, Inc., Abzena Ltd., Aenova Holding GmbH, AGC Biologics GmbH, Avid Bioservices, Inc., Binex Co. Limited, Boehringer Ingelheim International GmbH, Cambrex Corporation, Catalent, Inc., Emergent BioSolutions, Inc., Fujifilm Holdings Corporation, Icon PLC, JRS PHARMA GmbH & Co. KG, JSR Life Sciences, LLC, Lonza Group AG, Parexel International Corporation, ProBioGen AG, Recipharm AB, Rentschler Biopharma SE, Samsung Biologics, Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific, Inc., Toyobo Co., Ltd., and WuXi Biologics Inc..

The report offers valuable insights on the following aspects:
  1. Market Penetration: It provides comprehensive information about key players' market dynamics and offerings.
  2. Market Development: In-depth analysis of emerging markets and penetration across mature market segments, highlighting lucrative opportunities.
  3. Market Diversification: Detailed information about new product launches, untapped geographies, recent developments, and investments.
  4. Competitive Assessment & Intelligence: Exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of leading players.
  5. Product Development & Innovation: Intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
  1. What is the market size and forecast for the Biologics Contract Development Market?
  2. Which products, segments, applications, and areas hold the highest investment potential in the Biologics Contract Development Market?
  3. What is the competitive strategic window for identifying opportunities in the Biologics Contract Development Market?
  4. What are the latest technology trends and regulatory frameworks in the Biologics Contract Development Market?
  5. What is the market share of the leading vendors in the Biologics Contract Development Market?
  6. Which modes and strategic moves are suitable for entering the Biologics Contract Development Market?


Note: PDF & Excel + Online Access - 1 Year


1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Biologics Contract Development Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing demand for vaccine and biosimilar production
5.1.1.2. Government initiatives encouraging biologics activities
5.1.1.3. Improved operational efficiency and cost saving with biologics CDO
5.1.2. Restraints
5.1.2.1. Communication issues between end-user and CDO
5.1.3. Opportunities
5.1.3.1. Technological advancements in biologics development systems
5.1.3.2. Investments in new biologics contract development services expansion
5.1.4. Challenges
5.1.4.1. Concerns associated with breach of intellectual property
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of COVID-19
5.5. Cumulative Impact of Russia-Ukraine Conflict
5.6. Cumulative Impact of High Inflation
5.7. Porter’s Five Forces Analysis
5.7.1. Threat of New Entrants
5.7.2. Threat of Substitutes
5.7.3. Bargaining Power of Customers
5.7.4. Bargaining Power of Suppliers
5.7.5. Industry Rivalry
5.8. Value Chain & Critical Path Analysis
5.9. Regulatory Framework
5.10. Client Customization
6. Biologics Contract Development Market, by Source
6.1. Introduction
6.2. Mammalian
6.3. Microbial
7. Biologics Contract Development Market, by Type
7.1. Introduction
7.2. Molecular Therapy
7.3. Monoclonal Antibodies
7.4. Recombinant Proteins
7.5. Vaccines
8. Biologics Contract Development Market, by Disease Indication
8.1. Introduction
8.2. Cardiovascular Disorders
8.3. Hematological Disorders
8.4. Immunological Disorders
8.5. Oncology
9. Biologics Contract Development Market, by Phase
9.1. Introduction
9.2. Phase I
9.3. Phase II
9.4. Phase III
9.5. Preclinical
10. Biologics Contract Development Market, by Service Type
10.1. Introduction
10.2. Cell Line Development
10.3.1. Mammalian
10.3.2. Microbial
10.3. Process Development
10.4.1. Downstream
10.4.2.1. Impurity, Isolation, & Identification
10.4.2.2. Pharmaceutical Analysis
10.4.2.3. Physicochemical Characterization
10.4.2. Upstream
10.4.3.1. Mammalian
10.4.3.2. Microbial
11. Biologics Contract Development Market, by End-User
11.1. Introduction
11.2. Biopharmaceutical Companies
11.3. Research Laboratories
12. Americas Biologics Contract Development Market
12.1. Introduction
12.2. Argentina
12.3. Brazil
12.4. Canada
12.5. Mexico
12.6. United States
13. Asia-Pacific Biologics Contract Development Market
13.1. Introduction
13.2. Australia
13.3. China
13.4. India
13.5. Indonesia
13.6. Japan
13.7. Malaysia
13.8. Philippines
13.9. Singapore
13.10. South Korea
13.11. Taiwan
13.12. Thailand
13.13. Vietnam
14. Europe, Middle East & Africa Biologics Contract Development Market
14.1. Introduction
14.2. Denmark
14.3. Egypt
14.4. Finland
14.5. France
14.6. Germany
14.7. Israel
14.8. Italy
14.9. Netherlands
14.10. Nigeria
14.11. Norway
14.12. Poland
14.13. Qatar
14.14. Russia
14.15. Saudi Arabia
14.16. South Africa
14.17. Spain
14.18. Sweden
14.19. Switzerland
14.20. Turkey
14.21. United Arab Emirates
14.22. United Kingdom
15. Competitive Landscape
15.1. FPNV Positioning Matrix
15.2. Market Share Analysis, By Key Player
15.3. Competitive Scenario Analysis, By Key Player
16. Competitive Portfolio
16.1. Key Company Profiles
16.1.1. AbbVie, Inc.
16.1.2. Abzena Ltd.
16.1.3. Aenova Holding GmbH
16.1.4. AGC Biologics GmbH
16.1.5. Avid Bioservices, Inc.
16.1.6. Binex Co. Limited
16.1.7. Boehringer Ingelheim International GmbH
16.1.8. Cambrex Corporation
16.1.9. Catalent, Inc.
16.1.10. Emergent BioSolutions, Inc.
16.1.11. Fujifilm Holdings Corporation
16.1.12. Icon PLC
16.1.13. JRS PHARMA GmbH & Co. KG
16.1.14. JSR Life Sciences, LLC
16.1.15. Lonza Group AG
16.1.16. Parexel International Corporation
16.1.17. ProBioGen AG
16.1.18. Recipharm AB
16.1.19. Rentschler Biopharma SE
16.1.20. Samsung Biologics
16.1.21. Takeda Pharmaceutical Company Limited
16.1.22. Thermo Fisher Scientific, Inc.
16.1.23. Toyobo Co., Ltd.
16.1.24. WuXi Biologics Inc.
16.2. Key Product Portfolio
17. Appendix
17.1. Discussion Guide
17.2. License & Pricing

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings